What question did this study set out to answer?

This research aims to evaluate the impact of pertuzumab on pathological complete response rates in early HER2+ breast cancer.

Pertuzumab and Pathological Complete Response in Early HER2+ Breast Cancer: A Systematic Review and Meta-analysis of Real-World Studies

View Full Paper

Ask AI

Bookmark

Authors

Systematic review demonstrates improved pCR rates with pertuzumab in HER2+ breast cancer, suggesting wider adoption of dual HER2 blockade.

This research aims to evaluate the impact of pertuzumab on pathological complete response rates in early HER2+ breast cancer.
Conducted a systematic review and meta-analysis of real-world studies
Analyzed data on neoadjuvant therapy including pertuzumab
Evaluated rates of pathological complete response
Significant improvement in pCR rates with pertuzumab compared to standard treatment
Findings align with randomized controlled trial (RCT) evidence
Supports the adoption of dual HER2 blockade in early HER2+ breast cancer

Matsas et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Systematic review demonstrates improved pCR rates with pertuzumab in HER2+ breast cancer, suggesting wider adoption of dual HER2 blockade.